News - Myeloma Patients Europe

Latest News

Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”

March 8, 2024

After the diagnosis, it took almost a month to start the treatments. The first one was on my birthday, and I felt that the universe was giving me a unique opportunity. I did six cycles…

EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

February 23, 2024

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the…

US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myeloma

February 22, 2024

The US Food and Drug Administration (FDA – the medicines regulator in the US) has granted approval to a “supplemental biologics license application” for teclistamab-cqvy (Tecvayli®). This means the existing FDA teclistamab license has been extended to…

AMEN provides medical information for Arabic speakers in Israel and beyond

February 13, 2024

The population of Israel today is 9.8 million people. Among them, 20% are Arabs (about 2 million people) whose first language is Arabic. Due to this, the Israel Multiple Myeloma Association, AMEN, decided to promote…

GSK announces results from interim analysis of the DREAMM-7 phase III trial

February 8, 2024

On 6 February 2024, GlaxoSmithKline (GSK) announced results from an interim analysis of the DREAMM-7 phase III trial presented at an American Society of Clinical Oncology (ASCO) online plenary session. The trial is evaluating belantamab…

Sign up for the MPE webinar “Basics of medicines pricing in Europe”

January 31, 2024

Myeloma Patients Europe (MPE) will hold the webinar “Basics of medicines pricing in Europe” on Thursday 7th March 2024 from 15:00 – 16:30 CET. Through this webinar you will understand the basics of drug pricing…

EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

January 30, 2024

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed…

MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapy

December 19, 2023

MPE announces partnership with an international team, including representatives from scientific, industry, and healthcare sectors, as part of the EU-funded research project CERTAINTY, which began in December 2023. The EU consortium “CERTAINTY – A cellular…

September

October 2025

November

MO
TU
WE
TH
FR
SA
SU

29
30
1
2
3
4
5

6
7
8
9
10
11
12

13
14
15
16
17
18
19

20
21
22
23
24
25
26

27
28
29
30
31
1
2

Events for October

31st

No Events

Latest News

October 2025

Events for October

1st

Events for October

2nd

Events for October

3rd

Events for October

4th

Events for October

5th

Events for October

6th

Events for October

7th

Events for October

8th

Events for October

9th

Events for October

10th

Events for October

11th

Events for October

12th

Events for October

13th

Events for October

14th

Events for October

15th

Events for October

16th

Events for October

17th

Events for October

18th

Events for October

19th

Events for October

20th

Events for October

21st

Events for October

22nd

Events for October

23rd

Events for October

24th

Events for October

25th

Events for October

26th

Events for October

27th

Events for October

28th

Events for October

29th

Events for October

30th

Events for October

31st

PopUp